European Diabetes Forum to lobby for policy change

2 October 2018
european_diabetes_forum_eadf_big

At its annual meeting in Berlin, Germany, the European Association for the Study of Diabetes (EASD) has launched a new initiative, aimed at enabling “the sustainability of European healthcare systems to cope with the diabetes pandemic.”

Dubbed the European Diabetes Forum (EUDF), the new working group is being initiated in the context of an epidemic of the disease. It’s estimated that some 60 million Europeans have diabetes.

The EUDF says that most healthcare systems are “poorly fitted to the daily needs of the person with diabetes and fail to track the impact on lives, through complications that extend far beyond classical ‘diabetology’ and into many other medical fields.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical